About Celladon
Celladon is a company based in San Diego (United States) founded in 2000. Celladon has raised $117.02 million across 11 funding rounds from investors including Pfizer, Novartis and Kleiner Perkins. The company has 56 employees. Celladon offers products and services including Blog Platform and Article Services. Celladon operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 56
- Stage Public
- SectorsHealthcare
- Website celladon.net
- Social LinkedIn X
- Total Equity Funding$117.02M (USD)
in 11 rounds
- Latest Funding Round$39.5M (USD), Post-IPO
Nov 2015
- InvestorsPfizer
& 14 more
- Employee Count56
Products & Services of Celladon
Celladon offers a comprehensive portfolio of products and services, including Blog Platform and Article Services.
Provides articles on telecommunications and health for general readers.
Offers educational posts on investing and ecommerce topics online.
Funding Insights of Celladon
Celladon has successfully raised a total of $117.02M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $39.5 million completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $117.02M
- Total Rounds 11
- Last Round Post-IPO — $39.5M
- First Round $30M
(Dec 2005)
- Investors Count 15
Latest 10 of 11 funding rounds of Celladon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2015 | $39.5M | Post-IPO | – | – | |
| Oct 2013 | $1.1M | Debt – Conventional | – | – | – |
| May 2012 | $19.47M | Series D | – | MPM Capital | |
| Feb 2012 | $43M | Series D | – | Pfizer, Novartis | – |
| Dec 2011 | $500,000 | Debt – Conventional | – | – | – |
| Aug 2011 | $250,000 | Series C | – | – | – |
| Jun 2011 | $400,000 | Debt – Conventional | – | – | – |
| Oct 2010 | $2.5M | Series C | – | – | – |
| Dec 2009 | $3.5M | Debt – Conventional | – | – | – |
| Nov 2009 | $21.8M | Series C | – | – |
15 investors in total: 15 institutional.
Investors in Celladon
Celladon has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Novartis and Kleiner Perkins.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investing in IT and healthcare ventures. | – | interwest.com | - | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
- | – | gbsventures.com.au | - | |
Venture capital firm backed by Johnson & Johnson | – | jnjinnovation.com/jjdc | Cambridge, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Life science companies are funded through venture capital investments. | – | lundbeckfonden.com | Copenhagen, Denmark | |
- | – | epvc.com | - | |
Life science & tech focused VC firm investing in the US | – | domainvc.com | Princeton, United States |
Investor details for Celladon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Celladon
4 dated milestones of Celladon across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Celladon is founded.
- Funding First funding round of $30.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $39.5M.
Competitors of Celladon
Celladon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| eigerbio.com | 2000 | San Carlos, United States | $8.9M | 56 | Developer of antiviral agents against targets in the treatment of hepatitis | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| capricor.com | 2005 | Los Angeles, United States | – | 62 | Regenerative medicine for cardiovascular disorders is developed using cell-based platforms. | |
| cardurion.com | 2017 | Boston, United States | $270M | – | Therapeutics for heart and cardiovascular diseases are developed. | |
| esperion.com | 1998 | Ann Arbor, United States | $129.7M | 240 | Therapies for lowering low-density lipoprotein cholesterol levels are developed. | |
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. |
Detailed competitors of Celladon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Celladon
Websites that share an audience with Celladon (celladon.net).
Websites whose visitors overlap most with Celladon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| prosidion.com | 100% | – | – | View details | |
| biotrondiagnostics.com | 100% | 1.5K | #9,362,675 | View details | |
| bionovo.com | 100% | – | – | View details | |
| taigenbiotech.com | 100% | 1.8K | #8,037,594 | View details | |
phytopharm.com | phytopharm.com | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Celladon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Celladon
10 companies that operate in the same segment as Celladon (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Celladon
Celladon was founded in 2000 and raised its 1st funding round 5 years after it was founded.
Celladon is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Celladon is a funded company, having raised a total of $117.02M across 11 funding rounds to date. The company's 1st funding round was a Series C of $21.8M, raised on Dec 2005.
Celladon has 56 employees.
Celladon Corporation was established in 2000 as a biotechnology firm based in San Diego, United States. Molecular therapies targeting heart failure are developed and produced, with key products including SERCA2a for calcium regulation in heart cells and MYDICAR as an enzyme replacement option. Operations focus on enzyme-based treatments to address contractility issues. In March 2016, a merger with Eiger BioPharmaceuticals was completed, resulting in a name change to Eiger BioPharmaceuticals.
Celladon's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Celladon offers Blog Platform and Article Services.
Celladon has 15 investors. Key investors include Pfizer, Novartis, Kleiner Perkins, RA Capital, and Life Sciences Partners.